Vermillion
6611 Dumbarton Circle
Fremont
California
94555
United States
Tel: 510-505-2100
Fax: 510-505-2101
Website: http://www.vermillion.com/
266 articles about Vermillion
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women
12/17/2019
Study evaluates the differences in sensitivity of ovarian cancer risk detection between OVA1® Plus and CA125
-
Vermillion Announces Two Independent Publications Showing OVA1® (MIA- Multivariate Index Assay) Demonstrates Improved Ovarian Malignancy Risk Detection in African-American Women
9/4/2019
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the publication of two independent studies demonstrating that OVA1® (Blood Multivariate Index Assay (MIA) for Ovarian Cancer Risk Assessment) improves ovarian cancer risk detection in women compared to alternative technology, such as CA125 and CA125 & HE4 (Risk of Malignancy Algorithm ROMA)
-
Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone
7/16/2019
-Highest Performing Early Stage Ovarian Cancer Risk Assessment Available Today-
-
Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
2/5/2018
Vermillion announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1 and Overa.
-
Vermillion Announces Agreement with BlueCross BlueShield of Illinois
1/18/2018
ASPiRA LABS, a Vermillion company today announced it has entered into an agreement with BlueCross BlueShield of Illinois.
-
Vermillion Appoints Bob Beechey to Newly Created CFO Post
12/19/2017
Bob Beechey has served in numerous financial and operational leadership roles.
-
Vermillion Announces Publication of Foundational Health Economics Study
11/16/2017
The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (PMPM) level.
-
Vermillion Reports Third Quarter 2017 Results
11/8/2017
Conference call is scheduled for 4:30 p.m. ET today.
-
Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
11/6/2017
Vermillion announced today that Valerie Palmieri, President and CEO, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017.
-
ASPiRA Labs Announces a Major Coverage Milestone - a 27% Increase in Covered Lives for OVA1
11/1/2017
[01-November-2017] AUSTIN, Texas, Nov. 1, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced that it has substantially expanded positive policy coverage with the addition of 14 key managed care providers. This positive coverage is a transition from negative policy to positive policy f
-
Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th
10/26/2017
Vermillion announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
-
Vermillion Reports Second Quarter 2017 Results
8/10/2017
-
Vermillion Announces Date Change Of Second Quarter 2017 Financial Results And Investor Conference Call
8/4/2017
-
Vermillion To Report Second Quarter 2017 Financial Results And Host Investor Conference Call On August 8th
7/28/2017
-
Vermillion Reports First Quarter 2017 Results
5/11/2017
-
Vermillion To Report First Quarter 2017 Financial Results And Host Investor Conference Call On May 11
4/27/2017
-
Vermillion Reports Fourth Quarter And Full Year 2016 Results
3/30/2017
-
Vermillion Release: ASPiRA LABS Announces TriCare South Contract
3/30/2017